FabRx’s pharmaceutical 3D printer for personalised medicines, M3DIMAKER™, is now available!

April 06, 2020 | Featured

FabRx Ltd., the innovative pharmaceutical biotechnology spin-out from University College London (UCL) pioneering 3D printing of pharmaceuticals, has released the first pharmaceutical 3D printer M3DIMAKER™ for the manufacture of personalised medicines. The novel system was first introduced at the ILMAC Exhibition in Basel (Switzerland) on the 24th – 27th September 2019. FabRx is thrilled to announce that their cutting edge alternating nozzle 3D printing system, which has been tested in hospitals, pharmacies and research institutes around the world, has now been launched onto the market.


Currently, medicines are produced using mass manufacturing methods which creates dosage forms with identical characteristics (dosage, appearance and drug release). Such practices can lead to inappropriate dosing, resulting in undesirable side effects or lack of treatment effect in many patient populations (i.e. children and the elderly). In the case of paediatrics, tablets are often split or crushed to meet dosage requirements, which can lead to errors, inaccuracy and occasionally to the incorrect use of medicines. There is a clear need for age-appropriate formulations, however conventional manufacturing techniques have not made enough progress towards personalised medicines.

Sophisticated 3D printing technologies aim to truly deliver unique personalised medicines with appearance and dosages that can be tailored directly to the patient on demand. The ground-breaking additive manufacturing technology has the capability of producing Printlets™ (3D printed tablets) with a precise dose and can even combine multiple medications into a single ‘polypill’ for patients with complicated medication regimens.


Fig. 1. The M3DIMAKER™ printing a number of tablets directly onto pharmaceutical blister packaging.

FabRx’s breakthrough 3D printer, M3DIMAKER™, consists of a sleek hardware system that is controlled by specialised software, allowing the selection of the required dose by the pharmacist according to the prescription given by the clinician. Incorporation of a modern fingerprint access control alongside a data matrix reader ensures manufacturing reliability, as only qualified personnel will have access to the technology’s outstanding features.  Moreover, the system is fitted with advanced in-line quality control procedures alongside camera monitoring of the printing process to track the progress and detect any faults during manufacture. A choice between three different printing nozzles allows the user to adapt the system to their manufacturing needs. The M3DIMAKER™ has a large array of applications within drug development (e.g. manufacture of small batches for pre-clinical and clinical studies) as well as clinical practice (personalised medicines). Depending on the medicine being made, the preparation of one-month’s medication (28 printlets) can be carried out in ~8 minutes, revolutionising the drug manufacture timeline.

Dr. Alvaro Goyanes, Director of Development at FabRx stated that “We are delighted to be launching our state-of-the-art 3D printing system in light of the recommendations from the regulatory organisations into the pharmaceutical market. I truly believe that we are one step closer to personalised medicine thanks to the M3DIMAKER™.”

For more information or to purchase a printer for your requirements, please visit www.fabrx.co.uk/technologies and contact the team on info@fabrx.co.uk.


Background on FabRx

FabRx Ltd was established in 2014 by leading academics from University College London (UCL), and is recognised as a world leader in the application of 3D printing technology for medicines and medical devices. Since its initiation, FabRx has developed over seven different types of pharmaceutical 3D printers and in 2017 were awarded with the TCT Best Start Up Award. In 2018, FabRx were awarded a grant totalling near £1 million from Innovate UK to develop the world’s first personalised medicine 3D printer, and conducted a world first clinical study utilising their Printlets™ technology in 2019. Its founders have a wealth of experience in all aspects of oral drug formulation and knowledge of the challenges of bringing new medicines through regulatory processes of the pharmaceutical sector.


Global press contact:

FabRx Limited

29-39 Brunswick Square

London WC1N 1AX


Phone: 07454887793

Back to News

Copyright © 2021 FabRx Ltd